



**New York State Medicaid Drug Utilization Review (DUR) Board Meeting  
Room 3, Concourse Level, Empire State Plaza, Albany NY  
May 15, 2026  
9:00am to 4:00pm**

The meeting will be available for public viewing as a live and archived webcast  
[Department of Health Events and Webcasts](#)

---

**9:00 – 9:15 Welcome and Introductions**

---

**9:15 – 10:45 Public Comment Period**

---

**10:45 – 12:15 Preferred Drug Program (PDP) Review**

The DUR Board will review the therapeutic classes listed below, as they pertain to the PDP ([NYS Public Health Law, Sections 272 and 273](#)), and recommend drugs for preferred or non-preferred status. The review may also include updates to clinical criteria or coverage parameters. The Preferred Drug List (PDL), which includes preferred or non-preferred status and clinical criteria, may be viewed at: [NYRx Preferred Drug List](#). For therapeutic classes currently subject to the PDP, the DUR Board will only consider clinical information, which is new since the previous review of the therapeutic class and then consider financial information.

1. Antibiotics – Inhaled  
Previous Review Date: 5/13/2021
2. Antibiotics – Vaginal  
Initial Review  
Drugs in the therapeutic class: Cleocin (clindamycin), clindamycin, Clindesse (clindamycin), Xaciato (clindamycin), metronidazole, Nuversa (metronidazole), Vandazole (metronidazole)
3. Lipotropics – Other  
Initial Review  
Drugs in the therapeutic class: Praluent (alirocumab), Redemplo (plozasiran), Repatha (evolocumab), Tryngolza (olezarsen)
4. Pulmonary Arterial Hypertension (PAH) Agents, Other  
Previous Review Date: 9/20/2018
5. Immunomodulators & Related Agents – Topical  
Previous Review Date: 10/3/2025
6. Glucagon Agents  
Previous Review Date: 5/15/2025



- 
7. Growth Hormones  
Previous Review Date: 5/16/2024
  8. Insulin – Rapid Acting  
Previous Review Date: 5/15/2025
  9. Hemophilia Agents – Other  
Previous Review Date: 5/15/2025
  10. Immunomodulators – Systemic  
Previous Review Date: 10/3/2025

---

**12:15 – 12:45 Medicaid Drug Cap / Drug Utilization Review**

The DUR Board will review the following drug, which has been identified in the eightieth percentile or higher of total spend (net of rebate) or in the eightieth percentile or higher based on cost per claim (net of rebate) as per [New York State Public Health Law 280](#) and if applicable, recommend a supplemental rebate target amount, clinical criteria, or interventions to ensure appropriate utilization:

- Entyvio (vedolizumab)

---

**12:45 – 2:15 Lunch / Executive Session**

Preferred Drug Program and Medicaid Drug Cap Financial Reviews

---

**2:15 – 2:45 Preferred Drug Program and Medicaid Drug Cap Recommendations**

---

**2:45 – 3:15 Drug Utilization Review**

The DUR Board will review the following topic(s) and, if applicable, recommend clinical criteria and/or interventions to ensure appropriate drug utilization:

1. Treatment of Headaches with the following drug classes:
  - Butalbital-Containing Agents
  - Ergotamine Derivatives

---

**3:15 – 3:30 Pharmacy Program Updates**

1. Treatment of Ulcerative Colitis and Crohn's Disease inclusive of the following drug classes:
  - Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
  - Non-Specific Anti-Inflammatory Drugs

---

**3:30 – 4:00 Final Comments and Adjournment**



---

**The agenda timeline is subject to change based on meeting proceedings.**

---

### **Additional Information**

Parties interested in providing public comments during the DUR Board meeting, must complete the registration process by May 7, 2026. Requests to provide public comment may be made by calling 518-486-3209 or e-mailing [dur@health.ny.gov](mailto:dur@health.ny.gov) (please reference DUR Board Meeting Speaker Request).

Public comments are limited to items on the agenda. Comments must be brief (2 minutes), and the total comment period will not exceed ninety (90) minutes. The Department of Health (DOH) reserves the right to limit the number of interested parties providing public comment to meet agenda timelines and accomplish meeting objectives.

Written statements and clinical information can be sent to [dur@health.ny.gov](mailto:dur@health.ny.gov). Any studies cited should be referenced, with the primary source of funding included.

Written statements should summarize key points and may not exceed two (2) pages in length. Written statements must be received by May 7, 2026.

Any other clinical information must be received by April 30, 2026.

All information must be sent to the DOH. Interested parties should not contact or send any information directly to DUR Board members.

---

DUR Board Members may participate by [videoconferencing from a non-public location under extraordinary circumstances](#) if an unexpected factor or event precludes physical attendance.